Sign in
CAPR Stock Price, Chart, Stats & News
Capricor Therapeutics, Inc.
Save
Capricor Therapeutics, Inc. (CAPR) does not currently pay a dividend.
480.79M
Market cap
–
Current P/E
78.74x
Forward P/E
CAPR chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -29.51% |
ROE | -67.52% |
D/E | 0.07x |
Interest coverage ratio | -35.51x |
CAPR valuation
P/E | – |
P/S | – |
P/B | 4.62x |
P/CF | -20.22x |
P/FCF | -16.20x |
P/OCF | -20.22x |
PEG | 0.53x |
EV multiple | -15.12x |
About
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
Similar securities
Based on sector and market capitalization
Report issue